Royce & Associates LP Purchases 181,657 Shares of Certara, Inc. $CERT

Royce & Associates LP boosted its position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 6.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,937,683 shares of the company’s stock after buying an additional 181,657 shares during the period. Royce & Associates LP’s holdings in Certara were worth $27,027,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Central Pacific Bank Trust Division grew its holdings in Certara by 8.7% during the second quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock worth $127,000 after acquiring an additional 1,558 shares during the period. GAMMA Investing LLC raised its position in Certara by 21.2% in the third quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock worth $90,000 after acquiring an additional 1,710 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Certara by 12.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock valued at $117,000 after acquiring an additional 1,923 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Certara by 12.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock valued at $133,000 after acquiring an additional 2,513 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Certara by 28.1% in the 1st quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after acquiring an additional 2,871 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on CERT shares. UBS Group restated a “neutral” rating and set a $13.00 price objective on shares of Certara in a research report on Friday, November 6th. KeyCorp boosted their target price on shares of Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Jefferies Financial Group reissued a “hold” rating and set a $12.00 target price on shares of Certara in a research note on Friday, November 6th. TD Cowen raised their target price on shares of Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Finally, Barclays raised their target price on shares of Certara from $9.00 to $12.00 and gave the stock an “equal weight” rating in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.92.

Check Out Our Latest Stock Analysis on CERT

Certara Stock Performance

Shares of NASDAQ CERT opened at $11.57 on Monday. The stock’s fifty day simple moving average is $9.70 and its 200 day simple moving average is $7.40. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -27.55 and a beta of 1.30. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.29. Certara, Inc. has a 52-week low of $4.45 and a 52-week high of $12.61.

Certara (NASDAQ:CERT – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. Certara had a positive return on equity of 3.36% and a negative net margin of 16.14%. The business had revenue of $94.90 million during the quarter, compared to the consensus estimate of $92.01 million. During the same period in the prior year, the business posted $0.14 earnings per share. Certara’s revenue was down 9.3% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. As a group, sell-side analysts forecast that Certara, Inc. will post 0.21 earnings per share for the current fiscal year.

Certara Company Profile

(Free Report)

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.

Further Reading

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.